Volume Alert - CLVS 50.80 Clovis Oncology Inc $CLVS Hit a high today of 52.37 Closing the day 10:30 at 50.80 -2.98 -5.54% With a day low of 48.88 and a total volume of 1,630,288.
CLVS Recent Posts: http://investorshangout.com/Clovis-Oncology-Inc-CLVS-53711/
CLVS Clovis Oncology Inc Recent Headline News
CO-1686 Data Confirmed Efficacy, Take Advantage Of Weakness In Clovis Oncology Shares Ahead Of Rucaparib Outcomes Data
Dr. Paul Nunzio DeSantis, Pharm.D - at Seeking Alpha - 1 hr 36 mins ago
CLVS: 49.61 (-4.17), AZN: 75.44 (+1.46)
Clovis Lung Cancer Update Swings Momentum to Rival, Slightly
at The Street - Wed Nov 19, 8:38AM CST
Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.
CLVS: 49.61 (-4.17), AZN: 75.44 (+1.46)
Clovis off premarket after report on CO-1686
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:21AM CST
CLVS: 49.61 (-4.17)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:14AM CST
SGYP: 3.07 (+0.11), ANV: 1.76 (-0.28), VIPS: 22.60 (-1.11), CLVS: 49.61 (-4.17), SUNE: 21.40 (-0.08), SNSS: 2.22 (+0.15), CLF: 8.81 (-1.40), GSAT: 2.66 (+0.11), EJ: 8.65 (-0.88), OPLK: 24.17 (+2.92), LITB: 7.95 (+0.31)
Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)
Business Wire - Tue Nov 18, 5:36PM CST
--Median PFS of 10.4 months in clinical dose group; data continue to mature
CLVS: 49.61 (-4.17)
Clovis teams up with Glaxo on combo cancer therapy
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 6:20AM CST
CLVS: 49.61 (-4.17), GSK: 46.36 (+0.08)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST
URBN: 29.23 (+0.44), DHX: 11.01 (-0.27), ACT: 269.00 (-0.60), OME: 11.49 (-0.96), CLVS: 49.61 (-4.17), AVB: 157.21 (-1.04), PF: 32.58 (+0.10), RMTI: 10.22 (-0.06), GLW: 20.45 (+0.03), FOLD: 6.67 (-0.08)
Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline
Business Wire - Mon Nov 17, 4:00PM CST
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that they have entered into a clinical trial collaboration with GlaxoSmithKline LLC to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). The Phase 1/2 trial of rociletinib given in combination with trametinib is planned to start in 1H 2015. The trial is designed to assess the safety and activity of the combination in patients with EGFR mutant NSCLC who were previously treated with an EGFR tyrosine kinase inhibitor (TKI).
CLVS: 49.61 (-4.17), GSK: 46.36 (+0.08)
Clovis Oncology Announces First Patient Enrolled in TIGER-1 Study
Business Wire - Wed Nov 12, 4:28PM CST
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the Phase 2 portion of the seamless Phase 2/3 TIGER-1 (Third-Generation Inhibitor of Mutant EGFR in Lung Cancer) study has commenced with the dosing of the first patient at a U.S. study site. Rociletinib is the Company's novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the primary resistance mutation T790M.
CLVS: 49.61 (-4.17)
Clovis Oncology's (CLVS) CEO Presents at Credit Suisse 2014 Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:10PM CST
CLVS: 49.61 (-4.17)
Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:40PM CST
CLVS: 49.61 (-4.17)
Clovis misses 3Q profit forecasts
Automated Insights - Thu Nov 06, 6:39PM CST
BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Thursday reported a loss of $39.6 million in its third quarter.
CLVS: 49.61 (-4.17)
Clovis Oncology misses by $0.10
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:00PM CST
CLVS: 49.61 (-4.17)
Clovis Oncology Announces Third Quarter 2014 Operating Results
Business Wire - Thu Nov 06, 3:01PM CST
--$278.3 million raised in September sale of senior convertible notes
CLVS: 49.61 (-4.17)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST
BEBE: 2.58 (+0.01), ACET: 21.00 (-0.33), ANET: 77.00 (+0.20), FNGN: 32.34 (+0.05), CPST: 0.89 (+0.05), AUQ: 4.19 (+0.04), AMRN: 1.27 (-0.05), ED: 62.25 (-0.78), ENV: 52.90 (+0.09), FXCM: 16.32 (-0.17), BCEI: 36.97 (+0.14), GXP: 26.53 (-0.03), EAC: 11.15 (+0.02), DXCM: 50.98 (-0.61), CSC: 61.73 (-0.29), AEL: 26.89 (-0.12), HNSN: 0.81 (+0.01), CFN: 57.71 (-0.07), ANAC: 30.15 (-0.79), DAR: 18.88 (-0.12), GST: 4.10 (+0.15), ARC: 9.69 (-0.15), FIVN: 4.54 (-0.28), ELON: 1.83 (-0.06), FSLR: 48.79 (-0.67), EZPW: 10.72 (-0.08), ALIM: 5.55 (-0.14), FWM: 2.77 (-0.03), BRS: 69.99 (-0.06), ECOM: 17.77 (-0.52), FTEK: 4.05 (-0.06), CVT: 27.33 (+0.18), AL: 37.48 (+0.43), BBRG: 13.06 (+0.08), BPZ: 0.93 (-0.01), ECPG: 43.75 (-0.93), HTGC: 15.73 (+0.08), AIRM: 44.73 (-0.13), BNFT: 23.06 (-1.35), ENOC: 14.98 (-0.17), HPTX: 21.01 (+0.03), AGO: 24.75 (unch), FICO: 71.99 (+0.21), FF: 12.20 (-0.05), FI: 20.08 (-0.10), EVC: 5.54 (-0.01), EBS: 24.29 (+0.04), ABCO: 42.14 (-1.34), DIOD: 25.85 (-0.35), DIS: 89.27 (-1.01), EGOV: 17.55 (-0.16), APEI: 35.60 (-0.37), DVA: 74.86 (-0.37), CLVS: 49.61 (-4.17), HCI: 40.10 (-0.77), BRKR: 18.13 (-0.13), HGR: 19.98 (-0.19)
Clovis Oncology to Present at the 2014 Credit Suisse Healthcare Conference
Business Wire - Tue Nov 04, 3:07PM CST
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, the Company's President and CEO, will present at the 2014 Credit Suisse Healthcare Conference on Tuesday, November 11, at 2:00pm MST. The conference is being held at the Arizona Biltmore in Phoenix, Arizona.
CLVS: 49.60 (-4.18)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 102.16 (-1.55), CLVS: 49.60 (-4.18), ARWR: 5.90 (-0.05), ACHN: 13.25 (-0.06), MRK: 59.58 (-0.31), RTRX: 8.50 (-0.53), RGLS: 16.75 (-1.37), EPZM: 23.07 (-0.36), AGIO: 96.10 (+12.29), RMTI: 10.22 (-0.06), ARNA: 4.15 (-0.16), KERX: 15.30 (-0.24)
AstraZeneca's Lynparza a Step Closer to European Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 4:41PM CDT
The CHMP gave a positive opinion in favour of approving AstraZeneca's (AZN) Lynparza.
AGN: 213.56 (+0.19), CLVS: 49.60 (-4.18), AZN: 75.44 (+1.46), REGN: 417.88 (+4.66)
Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer
Business Wire - Thu Oct 23, 3:52PM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that its global Phase 2 study of lucitanib in patients with FGFR1-amplified squamous non-small cell lung cancer (NSCLC) has commenced and the first patient has been dosed at a U.S. study site. Lucitanib is the Company's oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a-ss).
CLVS: 49.60 (-4.18)
3 Beaten Down Biotech Stocks to Buy Now
George Budwell, The Motley Fool - Motley Fool - Thu Oct 23, 10:20AM CDT
Biotech stocks that crumble after a clinical or regulatory setback can turn out to be stellar long-term buys. Even so, it's critical to understand why the stock plunged in the first place, and how management plans on putting the company on track to...
DVAX: 14.50 (-0.17), CLVS: 49.60 (-4.18), CLDX: 19.13 (+1.41), AZN: 75.44 (+1.46), GSK: 46.36 (+0.08)
CLVS Recent Posts: http://investorshangout.com/Clovis-Oncology-Inc-CLVS-53711/
CLVS Clovis Oncology Inc Recent Headline News
CO-1686 Data Confirmed Efficacy, Take Advantage Of Weakness In Clovis Oncology Shares Ahead Of Rucaparib Outcomes Data
Dr. Paul Nunzio DeSantis, Pharm.D - at Seeking Alpha - 1 hr 36 mins ago
CLVS: 49.61 (-4.17), AZN: 75.44 (+1.46)
Clovis Lung Cancer Update Swings Momentum to Rival, Slightly
at The Street - Wed Nov 19, 8:38AM CST
Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.
CLVS: 49.61 (-4.17), AZN: 75.44 (+1.46)
Clovis off premarket after report on CO-1686
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:21AM CST
CLVS: 49.61 (-4.17)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:14AM CST
SGYP: 3.07 (+0.11), ANV: 1.76 (-0.28), VIPS: 22.60 (-1.11), CLVS: 49.61 (-4.17), SUNE: 21.40 (-0.08), SNSS: 2.22 (+0.15), CLF: 8.81 (-1.40), GSAT: 2.66 (+0.11), EJ: 8.65 (-0.88), OPLK: 24.17 (+2.92), LITB: 7.95 (+0.31)
Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)
Business Wire - Tue Nov 18, 5:36PM CST
--Median PFS of 10.4 months in clinical dose group; data continue to mature
CLVS: 49.61 (-4.17)
Clovis teams up with Glaxo on combo cancer therapy
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 6:20AM CST
CLVS: 49.61 (-4.17), GSK: 46.36 (+0.08)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST
URBN: 29.23 (+0.44), DHX: 11.01 (-0.27), ACT: 269.00 (-0.60), OME: 11.49 (-0.96), CLVS: 49.61 (-4.17), AVB: 157.21 (-1.04), PF: 32.58 (+0.10), RMTI: 10.22 (-0.06), GLW: 20.45 (+0.03), FOLD: 6.67 (-0.08)
Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline
Business Wire - Mon Nov 17, 4:00PM CST
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that they have entered into a clinical trial collaboration with GlaxoSmithKline LLC to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). The Phase 1/2 trial of rociletinib given in combination with trametinib is planned to start in 1H 2015. The trial is designed to assess the safety and activity of the combination in patients with EGFR mutant NSCLC who were previously treated with an EGFR tyrosine kinase inhibitor (TKI).
CLVS: 49.61 (-4.17), GSK: 46.36 (+0.08)
Clovis Oncology Announces First Patient Enrolled in TIGER-1 Study
Business Wire - Wed Nov 12, 4:28PM CST
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the Phase 2 portion of the seamless Phase 2/3 TIGER-1 (Third-Generation Inhibitor of Mutant EGFR in Lung Cancer) study has commenced with the dosing of the first patient at a U.S. study site. Rociletinib is the Company's novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the primary resistance mutation T790M.
CLVS: 49.61 (-4.17)
Clovis Oncology's (CLVS) CEO Presents at Credit Suisse 2014 Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:10PM CST
CLVS: 49.61 (-4.17)
Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:40PM CST
CLVS: 49.61 (-4.17)
Clovis misses 3Q profit forecasts
Automated Insights - Thu Nov 06, 6:39PM CST
BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Thursday reported a loss of $39.6 million in its third quarter.
CLVS: 49.61 (-4.17)
Clovis Oncology misses by $0.10
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:00PM CST
CLVS: 49.61 (-4.17)
Clovis Oncology Announces Third Quarter 2014 Operating Results
Business Wire - Thu Nov 06, 3:01PM CST
--$278.3 million raised in September sale of senior convertible notes
CLVS: 49.61 (-4.17)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST
BEBE: 2.58 (+0.01), ACET: 21.00 (-0.33), ANET: 77.00 (+0.20), FNGN: 32.34 (+0.05), CPST: 0.89 (+0.05), AUQ: 4.19 (+0.04), AMRN: 1.27 (-0.05), ED: 62.25 (-0.78), ENV: 52.90 (+0.09), FXCM: 16.32 (-0.17), BCEI: 36.97 (+0.14), GXP: 26.53 (-0.03), EAC: 11.15 (+0.02), DXCM: 50.98 (-0.61), CSC: 61.73 (-0.29), AEL: 26.89 (-0.12), HNSN: 0.81 (+0.01), CFN: 57.71 (-0.07), ANAC: 30.15 (-0.79), DAR: 18.88 (-0.12), GST: 4.10 (+0.15), ARC: 9.69 (-0.15), FIVN: 4.54 (-0.28), ELON: 1.83 (-0.06), FSLR: 48.79 (-0.67), EZPW: 10.72 (-0.08), ALIM: 5.55 (-0.14), FWM: 2.77 (-0.03), BRS: 69.99 (-0.06), ECOM: 17.77 (-0.52), FTEK: 4.05 (-0.06), CVT: 27.33 (+0.18), AL: 37.48 (+0.43), BBRG: 13.06 (+0.08), BPZ: 0.93 (-0.01), ECPG: 43.75 (-0.93), HTGC: 15.73 (+0.08), AIRM: 44.73 (-0.13), BNFT: 23.06 (-1.35), ENOC: 14.98 (-0.17), HPTX: 21.01 (+0.03), AGO: 24.75 (unch), FICO: 71.99 (+0.21), FF: 12.20 (-0.05), FI: 20.08 (-0.10), EVC: 5.54 (-0.01), EBS: 24.29 (+0.04), ABCO: 42.14 (-1.34), DIOD: 25.85 (-0.35), DIS: 89.27 (-1.01), EGOV: 17.55 (-0.16), APEI: 35.60 (-0.37), DVA: 74.86 (-0.37), CLVS: 49.61 (-4.17), HCI: 40.10 (-0.77), BRKR: 18.13 (-0.13), HGR: 19.98 (-0.19)
Clovis Oncology to Present at the 2014 Credit Suisse Healthcare Conference
Business Wire - Tue Nov 04, 3:07PM CST
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, the Company's President and CEO, will present at the 2014 Credit Suisse Healthcare Conference on Tuesday, November 11, at 2:00pm MST. The conference is being held at the Arizona Biltmore in Phoenix, Arizona.
CLVS: 49.60 (-4.18)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 102.16 (-1.55), CLVS: 49.60 (-4.18), ARWR: 5.90 (-0.05), ACHN: 13.25 (-0.06), MRK: 59.58 (-0.31), RTRX: 8.50 (-0.53), RGLS: 16.75 (-1.37), EPZM: 23.07 (-0.36), AGIO: 96.10 (+12.29), RMTI: 10.22 (-0.06), ARNA: 4.15 (-0.16), KERX: 15.30 (-0.24)
AstraZeneca's Lynparza a Step Closer to European Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 4:41PM CDT
The CHMP gave a positive opinion in favour of approving AstraZeneca's (AZN) Lynparza.
AGN: 213.56 (+0.19), CLVS: 49.60 (-4.18), AZN: 75.44 (+1.46), REGN: 417.88 (+4.66)
Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer
Business Wire - Thu Oct 23, 3:52PM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that its global Phase 2 study of lucitanib in patients with FGFR1-amplified squamous non-small cell lung cancer (NSCLC) has commenced and the first patient has been dosed at a U.S. study site. Lucitanib is the Company's oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a-ss).
CLVS: 49.60 (-4.18)
3 Beaten Down Biotech Stocks to Buy Now
George Budwell, The Motley Fool - Motley Fool - Thu Oct 23, 10:20AM CDT
Biotech stocks that crumble after a clinical or regulatory setback can turn out to be stellar long-term buys. Even so, it's critical to understand why the stock plunged in the first place, and how management plans on putting the company on track to...
DVAX: 14.50 (-0.17), CLVS: 49.60 (-4.18), CLDX: 19.13 (+1.41), AZN: 75.44 (+1.46), GSK: 46.36 (+0.08)
